Posts by: Janet Stewart, MSc

Janet Stewart, MSc

Janet Stewart is a life sciences writer and editor, who completed both PhD course work and oral examinations in the Department of Microbiology and Immunology at McGill University, and holds an M.Sc. in Virology and Immunology.

December 18, 2017December 18, 2017

Genentech’s New Combo Therapy Improves Progression-free Survival in Advanced Non-small Cell Lung Cancer

Lung Cancer, News

Progression-free survival (PFS) was improved in patients with advanced non-squamous non-small cell lung cancer (NSCLC) using a combination of Avastin (bevacizumab), Tecentriq (atezolizumab), and chemotherapy in a Phase 3 clinical ... Read more

October 2, 2017October 2, 2017

Prometic Gets FDA Approval to Start Phase 2/3 Trial of PBI-4050 in IPF Patients

Idiopathic Pulmonary Fibrosis, News

Prometic Life Sciences announced that PBI-4050, its investigational therapy for idiopathic pulmonary fibrosis (IPF), has been cleared by the U.S. Food and Drug Administration (FDA) to enter a Phase 2/3 combination-treatment trial in the ... Read more

September 26, 2017September 26, 2017

Keytruda Approved in Canada for Treatment of Metastatic NSCLC

News

Merck’s Keytruda (pembrolizumab) is now available as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) in Canada. Adults whose tumors express high PD-L1, along with a ... Read more

September 20, 2017September 20, 2017

FibroGen’s Pamrevlumab Slows Lung Function Decline in IPF Patients, Trial Results Show

Idiopathic Pulmonary Fibrosis, News

Lung function decline in patients with idiopathic pulmonary fibrosis (IPF) was slowed by the investigational drug pamrevlumab, according to the results from a Phase 2b clinical trial. The results were presented ... Read more

August 29, 2017August 29, 2017

Three Share British Lung Foundation Grant for Lung Disease Research

Bronchiectasis, COPD, Idiopathic Pulmonary Fibrosis, News

Toby Maher, MD, a professor at Imperial College London and based at the National Heart and Lung Institute, is one of three researchers who were awarded the prestigious Chair in Respiratory Research grant ... Read more

June 19, 2017June 19, 2017

Australian Pulmonary Fibrosis Registry Offers Real-world Insight Into the Disease

Idiopathic Pulmonary Fibrosis, News

Patients in the Australian Idiopathic Pulmonary Fibrosis Registry who take anti-fibrotic therapies tend to live longer than those who do not, according to an analysis of the records. Another finding ... Read more

May 2, 2017May 2, 2017

Bellerophon’s INOpulse Shows Promising Results in Patients with PH-IPF Lung Disease

Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

Inhaled nitric oxide (iNO) treatment with the investigational medical device INOpulse system in patients with pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF) has shown promising results in a Phase 2 clinical ... Read more

April 11, 2017April 11, 2017

Researchers Review Performance of Genentech’s Esbriet in Treating Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis, News

Genentech’s Esbriet (pirfenidone), approved by the U.S. Food and Drug Administration (FDA) in 2014 to treat idiopathic pulmonary fibrosis (IPF), prolongs survival in patients and is generally safe, concludes a review, “Role ... Read more

April 3, 2017April 3, 2017

Stem Cells Reduce Lung Inflammation and Damage in Mouse Model of COPD and Cystic Fibrosis

COPD, Cystic Fibrosis, News

A ground-breaking experiment using mesenchymal stem cells (MSCs) injected into mice models of chronic obstructive pulmonary disease (COPD) and cystic fibrosis showed that MSC therapy might be a promising approach to ... Read more

January 30, 2017January 30, 2017

‘Mini Lungs’ May Help Determine Which Therapies Best Suit Patients with IPF

Idiopathic Pulmonary Fibrosis, News

“Mini lungs” created from the tissue of idiopathic pulmonary fibrosis (IPF) patients could be used to predict which of two medications would effectively treat them, according to a new study. The lung ... Read more